Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

News Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen
Other stock markets
 10:59:31 2024-05-31 am EDT 		5-day change 1st Jan Change
1,937 DKK +0.31% Intraday chart for Genmab A/S +0.55% -10.12%
May. 21 Genmab A/S Reaffirms Financial Guidance for 2024 CI
May. 21 Genmab A/S completed the acquisition of ProfoundBio, Inc. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Genmab A/S : Investigational Acasunlimab (DuoBody® PD L1x4 1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non small Cell Lung Cancer (mNSCLC)
PU
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BU
Transactions in Connection with Share Buy-back Program
GL
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
BU
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Genmab Completes Acquisition of ProfoundBio
BU
Genmab Completes Acquisition of ProfoundBio
GL
Genmab A/S Reaffirms Financial Guidance for 2024
CI
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S completed the acquisition of ProfoundBio, Inc.
CI
Legal Limbo: Genmab's Ofatumumab SPC Dilemma Heads To CJEU
AQ
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
MT
Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50%
MT
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
BU
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress
CI
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GL
Transactions in Connection with Share Buy-back Program
GL
Genmab A/S : has published its Articles of Association
PU
Genmab A/S : Articles of association dated May 07, 2024 – English
PU
Capital Increase in Genmab as a Result of Employee Warrant Exercise
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. News Genmab A/S